Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model

Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model

Objective. B lymphocyte-induced maturation protein 1 (Blimp-1) and programmed cell death protein 1 (PD-1) have opposing roles in the development of T cells; however, the mechanism of autoimmune thyroiditis- (AIT-) associated abortion is unclear. The present study investigated the expression of Blimp...

Full description

Bibliographic Details
Main Authors:	Xue Zhang, Xiaoshu Lv, Mengya Chen, Haixia Liu
Format:	Article
Language:	English
Published:	Hindawi Limited 2020-01-01
Series:	International Journal of Endocrinology
Online Access:	http://dx.doi.org/10.1155/2020/6543593

Similar Items

Reduced expression of PD-L1 in autoimmune thyroiditis attenuate trophoblast invasion through ERK/MMP pathway
by: Mengya Chen, et al.
Published: (2019-10-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade
by: Zia Khan, et al.
Published: (2021-06-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
by: YU Lin, et al.
Published: (2021-08-01)

PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis
by: Stephanie Schneider, et al.
Published: (2017-05-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
by: Kazuhiko Hashimoto, et al.
Published: (2021-07-01)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
by: Dongxu Wang, et al.
Published: (2019-04-01)

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
by: Qingshui Wang, et al.
Published: (2017-11-01)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
by: Ilcus C, et al.
Published: (2017-04-01)

Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions
by: Eun-Hye Kim, et al.
Published: (2020-05-01)

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
by: Zhengyi Wang, et al.
Published: (2020-11-01)

Human Herpesvirus and the Immune Checkpoint PD-1/PD-L1 Pathway: Disorders and Strategies for Survival
by: Takayuki Murata
Published: (2021-04-01)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
by: Akintunde Akinleye, et al.
Published: (2019-09-01)

Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
by: Iris Koopmans, et al.
Published: (2018-08-01)

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
by: Lisa Derosa, et al.
Published: (2018-06-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
by: Edyta Zyla, et al.
Published: (2021-08-01)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
by: Bogang Wu, et al.
Published: (2018-11-01)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
by: Xin Wang, et al.
Published: (2019-02-01)

Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
by: Chang Liu, et al.
Published: (2021-04-01)

Investigation of the PD-1 and PD-L1 Immune Checkpoint Molecules Throughout Healthy Human Pregnancy and in Nonpregnant Women
by: Matyas Meggyes, et al.
Published: (2020-08-01)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
by: Weijie Ma, et al.
Published: (2016-05-01)

Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer
by: Samia S. Messeha, et al.
Published: (2021-05-01)

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
by: Yongshu Li, et al.
Published: (2016-07-01)

Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
by: Yi-Chi eKong, et al.
Published: (2014-05-01)

Soluble forms of immune checkpoint receptor PD-1 and its ligand PD-L1 in plasma of patients with ovarian neoplasms
by: E. S. Gershtein, et al.
Published: (2018-12-01)

Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies)
by: Ruriko Ono, et al.
Published: (2019-07-01)

Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?
by: Puneet Singh, et al.
Published: (2019-02-01)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
by: Jan-Malte Placke, et al.
Published: (2021-09-01)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
by: Hao Zhang, et al.
Published: (2021-06-01)

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
by: Jee Hee Yoon, et al.
Published: (2021-04-01)

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
by: Victor C. Kok, et al.
Published: (2020-02-01)

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
by: Luisa Maria Griewing, et al.
Published: (2021-03-01)

Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
by: Ching-Yao Yang, et al.
Published: (2020-06-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Engineering Chimeric Antigen Receptor T-cells Against Immune Checkpoint Inhibitor PD1 and PD-L1 for Treating Pancreatic Cancer
by: Ming-Huei Fan, et al.
Published: (2018)

Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors
by: Philipp Schubert, et al.
Published: (2020-10-01)

A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer
by: Fan Z, et al.
Published: (2019-03-01)

Cannot write session to /tmp/vufind_sessions/sess_4ps8354hmg2lj86cmumacfvgb4